Search

everythinglearnresearchcommunity

for

Search:↓

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

Caffeine intake may increase DHT levels, but its impact on hair loss is minimal compared to genetic factors. Excessive caffeine can cause health issues, and its effects on hair loss are not directly applicable to humans based on rat studies.

The conversation discusses unconventional methods for hair regrowth, including scalp trauma like burning or microneedling, and compares them to treatments like Minoxidil and Finasteride. It highlights skepticism about these methods and the body's unpredictable healing responses.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The user suspects scarring alopecia and is exploring NSAIDs and turmeric/pepper for inflammation-related hair loss, having experienced burning and thinning with finasteride and testosterone reduction. They are seeking feedback while unable to afford a dermatologist.

A user's experience with microneedling monotherapy and potential treatments such as finasteride, minoxidil, Stemoxydine, rosemary oil, peppermint oil, and RU58841 for reversing hair loss.

Hair loss affects self-esteem and mental health, with treatments like finasteride and minoxidil commonly used. People feel misunderstood by those without hair loss and seek more empathy and better treatment options.

Fluridil may decrease the number of androgen receptors in hair follicles by up to 95%. This suggests a different action mechanism from other non-steroidal antiandrogens like RU58841, indicating they might be used together.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

Finasteride can affect hormone levels, potentially causing symptoms like puffy nipples and testicular pain, and may result in elevated prolactin and high testosterone. The user is seeking interpretation of these changes after taking finasteride.

A user describes using a Dermastamp for microneedling their scalp, noting a crunching sound when pressing it firmly. Another user suggests the crunching might be from breaking up scalp calcification.

A user experienced increased shedding after adding KX-826 to their long-term finasteride and minoxidil regimen. Another user reported mild side effects from KX-826, such as stomach and testicle pain.

The conversation discusses disappointment in Verteporfin for hair loss treatment, with a mention of an upcoming trial by Dr. Bisanga. No specific treatments were confirmed as used by the original poster.

The conversation discusses microneedling for hair loss, with one user trying 0.3mm daily without feeling pain and questioning its effectiveness. Another user suggests that 0.3mm is too shallow and recommends 0.5mm twice a week or 0.75mm once a week for hair growth.

Stopping antihistamines may resolve neurological side effects when using finasteride. Users experienced muscle aches, headaches, and lethargy when combining the two.

The conversation is about a user experiencing hair thinning potentially due to excessive microneedling while using finasteride and minoxidil. Many suggest reducing microneedling frequency and considering alternative treatments like dutasteride or a hair transplant.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

Adderall and Vyvanse may contribute to hair loss by stressing the dopamine system and increasing cortisol levels. Users discuss potential treatments like Minoxidil, finasteride, and RU58841 for managing hair loss.

A user inquired about Hair XL offered by a clinic in the Netherlands, questioning if it is a form of Exosome treatment. The conversation seeks experiences and clarity on the treatment.

Caffeine might raise stress hormones, potentially worsening hair loss. Telogen effluvium is often misattributed to minor stressors rather than significant life events.

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

Nizoral causes scalp and face itchiness and flakes. Piroctone olamine is suggested as an alternative.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.